Skip to main content

Table 1 Baseline characteristics at time of NRTI switching (week 0) between the two groups

From: Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens

Baseline characteristics

EFV group

N = 28

NVP group

N = 34

P value

Gender: Female

8 (29%)

13 (38%)

0.590

Age, years, mean ± SD

35.5 ± 6.9

38.7 ± 8.3

0.110

Body weight, kilograms, mean ± SD

62.3 ± 9.8

62.7 ± 11.0

0.888

CD4 count, cells/mm3, mean ± SD

342 ± 147

381 ± 154

0.307

Serum creatinine, mg/dL, mean ± SD

0.78 ± 0.22

0.76 ± 0.16

0.758

eGFR, mL/min, median (IQR)

116 (98-134)

105 (188-123)

0.195

Serum phosphorus, mg/dL, mean ± SD

3.0 ± 0.5

3.0 ± 0.7

0.952

Serum uric acid, mg/dL, mean ± SD

5.1 ± 1.3

5.3 ± 1.6

0.575

Serum magnesium, mg/dL, mean ± SD

0.87 ± 0.23

0.92 ± 0.20

0.391

Serum alkaline phosphatase, mg/dL, mean ± SD

87 ± 23

89 ± 24

0.743